Risk of Uterine Cancers Increased in Breast Cancer Patients Treated With Tamoxifen
After adjustment for confounding variables, the risk of endometrial cancer was increased almost 4-fold with tamoxifen treatment.
Gynecologic, Ovarian, and Cervical Cancer News
GYNECOLOGIC CANCER ADVISOR
Incidence of Cervical Cancer on the Rise in Patients Aged 30-34 Years
New data show that, in the last 2 decades, the incidence of cervical cancer in the United States has declined or remained stable for most age groups.
Cancer Screening and Detection Remain Below Prepandemic Levels
Screening for breast, cervical, and colorectal cancer decreased from prepandemic levels in early 2020, rebounded in late 2020, and decreased again in 2021.
Barriers to Access Do Not Fully Explain Disparities in Ovarian Cancer Treatment
Non-Hispanic Black patients are less likely than Hispanic or non-Hispanic White patients to receive guideline-recommended treatment for ovarian cancer.
Prolonging Bevacizumab Treatment Does Not Improve PFS or OS in Ovarian Cancer
Fifteen months of bevacizumab should remain the standard for patients with ovarian cancer receiving chemotherapy after cytoreductive surgery, researchers say.
Elahere Granted Accelerated Approval for Platinum-Resistant Ovarian Cancer
The approval was based on data from the SORAYA trial.
GSK: Zejula Use for Second-Line Maintenance Treatment Restricted
The decision to restrict the indication follows an FDA review of the phase 3 ENGOT-OV16/NOVA trial.
ROCA Surveillance of Women With BRCA1/2 Mutations Feasible in Real World
Ovarian cancer surveillance using the Risk of Ovarian Cancer Algorithm (ROCA) is effective in the real world, a study suggests.
MYC Inhibitor Can Stave Off Progression in Patients With Advanced Solid Tumors
In a first-in-human trial of patients with solid tumors, a MYC inhibitor appeared tolerable and enabled nearly half of evaluable patients to maintain stable disease.
Underrepresentation in Cancer Trials May Not Be Driven by Ineligibility
Black and White patients were similarly likely to be eligible for cancer trials and to be offered enrollment.
Bevacizumab Biosimilar Alymsys Now Available
Alymsys (bevacizumab-maly), a biosimilar to Avastin (bevacizumab), has been made available by Amneal Pharmaceuticals.
ASCO Updates Guidelines for PARP Inhibitors in Ovarian Cancer
The update was prompted by data from phase 3 trials showing positive and negative results with PARP inhibitors.
Sexual Dysfunction May Be Common Among Women With Cancer
In a cohort of nearly 700 women with cancer, more than 60% reported some type of sexual dysfunction.
CHEK2 Pathogenic Variants Associated With Breast and Other Cancers
A retrospective evaluation of lab results linked the likelihood of certain cancer types with the presence of specific pathogenic variants in CHEK2.
Vaccine-Pembrolizumab Combo Appears Active in HPV+ Advanced Cervical Cancer
Combination treatment with the GX-188E vaccine and pembrolizumab can elicit responses in patients with HPV 16-/18-positive advanced cervical cancer.
Ovarian Tumor Sidedness Not Associated With Prognosis
Among patients with unilateral tumors, the risk of death was similar regardless of whether the tumor was left- or right-sided.
SOLO1: Olaparib Maintenance Continues to Provide Clinical Benefit at 7 Years
Olaparib maintenance can provide a clinical benefit for up to 7 years in patients with BRCA-mutated, advanced ovarian cancer, new data suggest.
Rucaparib Disappoints in Heavily Pretreated, BRCA1/2-Mutated Ovarian Cancer
Updated results from the ARIEL4 trial prompted Clovis Oncology to withdraw the approval for rucaparib as a treatment for BRCA-mutated ovarian cancer after 2 or more lines of chemotherapy.
Adding Atezolizumab to Chemo Does Not Improve PFS in Relapsed Ovarian Cancer
In the phase 3 ATALANTE study, adding atezolizumab to platinum-based chemotherapy did not improve progression-free survival in patients with relapsed ovarian cancer.
Gap in Routine Distress Screening Among Lung or Ovarian Cancer Survivors
A review of patient records revealed that survivors of some cancers do not undergo routine distress screening, regardless of race, age, ethnicity, and other characteristics.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Gynecologic Cancer
Loading... 
Loading...